Variant · Snv

NRAS Q61

CI-VAR-00003558Explore in graph →ClinVar 73058 CIViC 94 rs121913254

Curated evidence

Evidence by cancer (9 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–9 of 9 evidence items across 4 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Cutaneous Melanoma2
NRAS Q61	Binimetinib	Predictive	B	Supports Sensitivity Response	2	accepted	EID1226 Phase 2 study of MEK162 in patients with advanced melanoma and NRAS or BRAF mutation. 71 patients were enrolled, 6/30 patients with NRAS mutation had a partial response (Gln61Leu 1 Patient, Gln61Lys 9… (full text at CIViC) PMID 23414587 · Ascierto et al., 2013 · Open in CIViC	civic
NRAS Q61	Selumetinib	Predictive	C	Supports Sensitivity Response	2	accepted	EID1473 Phase 1 trial in 57 patients with advanced cancers treated with selumetinib. 4 melanoma patients had NRAS Q61 mutations. One patient with NRAS mutation had 70% tumor shrinkage after three cycles of se… (full text at CIViC) PMID 18390968 · Adjei et al., 2008 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
73058	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications	1	Large congenital melanocytic nevus; Neurocutaneous melanocytosis; Vascular Tumors Including Pyogenic Granuloma; Ras Inhibitor response; RASopathy; Neoplasm; Colorectal cancer; Epidermal nevus; Alveolar rhabdomyosarcoma; Spitzoid melanoma; Embryonal rhabdomyosarcoma; Atypical teratoid rhabdoid tumor; Melanoma; Neuroblastoma; Malignant peripheral nerve sheath tumor; NRAS-related disorder

Malignant Colorectal Neoplasm2
NRAS Q61	Cetuximab	Predictive	B	Does Not Support Resistance	3	accepted	EID124 In chemotherapy-refractory patients with colorectal cancer, NRAS mutation status (primarily Q61, N=13) was not informative for disease control rate, progression free survival or overall survival follo… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
NRAS Q61	Cetuximab + ChemotherapyCombination	Predictive	B	Supports Resistance	2	accepted	EID36 Chemotherapy-refractory patients with KRAS wt metastatic colorectal cancer harboring NRAS mutation (primarily Q61, n=10) have a significantly lower response rate to cetuximab than patients wildtype fo… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic

Malignant Colorectal Neoplasm2

NRAS Q61

Cetuximab

Predictive

Does Not Support Resistance

accepted

EID124

In chemotherapy-refractory patients with colorectal cancer, NRAS mutation status (primarily Q61, N=13) was not informative for disease control rate, progression free survival or overall survival follo… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

civic

NRAS Q61

Cetuximab + ChemotherapyCombination

Predictive

Supports Resistance

accepted

EID36

Chemotherapy-refractory patients with KRAS wt metastatic colorectal cancer harboring NRAS mutation (primarily Q61, n=10) have a significantly lower response rate to cetuximab than patients wildtype fo… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

civic

Melanoma2
NRAS Q61	(diagnostic)	Diagnostic	B	Supports Positive	3	accepted	EID10 Melanoma associated with NRAS Q61 mutation was more often associated with those at the extremity than those at the trunk. PMID 23861977 · Tschandl et al., 2013 · Open in CIViC	civic
NRAS Q61	Vemurafenib	Predictive	B	Supports Resistance	4	accepted	EID14 Vemurafenib resistance is associated with gain of Q61 mutation in NRAS. PMID 23569304 · Trunzer et al., 2013 · Open in CIViC	civic

Melanoma2

NRAS Q61

(diagnostic)

Diagnostic

Supports Positive

accepted

EID10

Melanoma associated with NRAS Q61 mutation was more often associated with those at the extremity than those at the trunk.

PMID 23861977 · Tschandl et al., 2013 · Open in CIViC

civic

NRAS Q61

Vemurafenib

Predictive

Supports Resistance

accepted

EID14

Vemurafenib resistance is associated with gain of Q61 mutation in NRAS.

PMID 23569304 · Trunzer et al., 2013 · Open in CIViC

civic

Thyroid Gland Follicular Carcinoma3
NRAS Q61	(prognostic)	Prognostic	B	Supports N/A	3	accepted	EID497 In patients with follicular thyroid carcinoma, those with mutations in NRAS at codon 61 did not have significantly different overall survival than patients with wild-type NRAS (p=0.36). PMID 22650231 · Fukahori et al., 2012 · Open in CIViC	civic
NRAS Q61	(prognostic)	Prognostic	B	Does Not Support Poor Outcome	2	accepted	EID6959 Follicular thyroid cancers harboring RAS mutations have limited aggressiveness in the absence of TERT mutations. 2/2 follicular thyroid cancer patients with co-mutations in NRAS (10 Q61R and 1 Q61K) o… (full text at CIViC) PMID 25448848 · Muzza et al., 2015 · Open in CIViC	civic
NRAS Q61	(prognostic)	Prognostic	B	Supports Poor Outcome	2	submitted	EID7104 Retrospective analysis of thyroid carcinoma patients from a single institution identified 33/58 patients with follicular carcinomas had any RAS mutations (NRAS, KRAS, or HRAS at codons 12 or 61), 22 o… (full text at CIViC) PMID 22650231 · Fukahori et al., 2012 · Open in CIViC	civic

Thyroid Gland Follicular Carcinoma3

NRAS Q61

(prognostic)

Prognostic

Supports N/A

accepted

EID497

In patients with follicular thyroid carcinoma, those with mutations in NRAS at codon 61 did not have significantly different overall survival than patients with wild-type NRAS (p=0.36).

PMID 22650231 · Fukahori et al., 2012 · Open in CIViC

civic

NRAS Q61

(prognostic)

Prognostic

Does Not Support Poor Outcome

accepted

EID6959

Follicular thyroid cancers harboring RAS mutations have limited aggressiveness in the absence of TERT mutations. 2/2 follicular thyroid cancer patients with co-mutations in NRAS (10 Q61R and 1 Q61K) o… (full text at CIViC)

PMID 25448848 · Muzza et al., 2015 · Open in CIViC

civic

NRAS Q61

(prognostic)

Prognostic

Supports Poor Outcome

submitted

EID7104

Retrospective analysis of thyroid carcinoma patients from a single institution identified 33/58 patients with follicular carcinomas had any RAS mutations (NRAS, KRAS, or HRAS at codons 12 or 61), 22 o… (full text at CIViC)

PMID 22650231 · Fukahori et al., 2012 · Open in CIViC

civic